Akebia Therapeutics (AKBA) Debt to Equity (2018 - 2025)
Akebia Therapeutics (AKBA) has disclosed Debt to Equity for 8 consecutive years, with $1.48 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity rose 288.08% to $1.48 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.48, a 288.08% increase, with the full-year FY2025 number at $1.48, up 288.08% from a year prior.
- Debt to Equity was $1.48 for Q4 2025 at Akebia Therapeutics, up from $1.15 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $12.63 in Q4 2022 to a low of -$2.63 in Q1 2023.
- A 5-year average of $1.28 and a median of $0.63 in 2021 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: soared 1026.32% in 2022, then tumbled 195.17% in 2023.
- Akebia Therapeutics' Debt to Equity stood at $1.32 in 2021, then skyrocketed by 858.6% to $12.63 in 2022, then crashed by 108.98% to -$1.13 in 2023, then soared by 30.63% to -$0.79 in 2024, then surged by 288.08% to $1.48 in 2025.
- Per Business Quant, the three most recent readings for AKBA's Debt to Equity are $1.48 (Q4 2025), $1.15 (Q3 2025), and $1.61 (Q2 2025).